Inhibikase Therapeutics I...

NASDAQ: IKT · Real-Time Price · USD
1.68
-0.02 (-1.18%)
At close: Aug 20, 2025, 3:59 PM
1.68
0.00%
After-hours: Aug 20, 2025, 04:10 PM EDT

Inhibikase Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 26.27K n/a n/a n/a n/a 79.57K 116.41K 64.52K 123.44K n/a 6.55K 46.03K 1.94K 328.46K 1.36M 1.41M
Cost of Revenue
24.16K 12.65K n/a 6.57K 6.57K 6.57K 6.57K 6.57K 159.2K 5.04K 5.04K n/a 2.98M 3.02M 3.39M 3.15M 2.38M 2.43M
Gross Profit
-24.16K -12.65K 13.14K -6.57K -6.57K -6.57K -6.57K 73K -42.79K 59.48K 118.4K n/a -2.98M -2.97M -3.39M -2.83M -1.02M -1.02M
Operating Income
-10.83M -14.6M -12.93M -5.83M -5.05M -4.78M -4.4M -4.77M -6.2M -4.71M -4.33M -4.51M -4.64M -4.64M -5.04M -4.47M -2.63M -2.63M
Interest Income
916.75K 919.27K 796.12K 49.41K 90.93K 132.72K 225.63K 173.68K 424.44K 237.17K 55.92K 18.54K n/a n/a n/a n/a n/a n/a
Pretax Income
-9.92M -13.68M -12.13M -5.78M -4.96M -4.65M -4.18M -4.6M -5.78M -4.48M -4.28M -4.49M -4.64M -4.64M -5.04M -4.47M -2.64M -2.64M
Net Income
-9.92M -13.68M -12.13M -5.78M -4.96M -4.65M -4.18M -4.6M -5.78M -4M -4.17M -4.49M -4.64M -4.64M -5.04M -4.47M -2.64M -2.64M
Selling & General & Admin
5.92M 5.25M 5.74M 1.64M 1.97M 2.02M 1.39M 1.62M 1.78M 1.93M 1.34M 1.54M 1.66M 1.67M 1.65M 1.64M 1.61M 1.6M
Research & Development
5.27M 10.51M 7.19M 4.19M 3.08M 2.75M 3M 3.23M 4.54M 2.85M 3.05M 2.98M 2.98M 3.02M 3.39M 3.15M 2.38M 2.43M
Other Expenses
-358.42K -1.16M n/a n/a n/a n/a n/a n/a n/a -64.52K -63.57K n/a -6.55K -46.03K n/a n/a n/a n/a
Operating Expenses
10.83M 14.6M 12.93M 5.83M 5.05M 4.78M 4.4M 4.77M 6.2M 4.71M 4.33M 4.51M 4.64M 4.64M 5.04M 4.47M 2.63M 2.63M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 5.00 158.00 157.00 7.81K 11.8K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
10.83M 14.6M 12.93M 5.83M 5.05M 4.78M 4.4M 4.77M 6.2M 4.71M 4.33M 4.51M 4.64M 4.64M 5.04M 4.47M 2.63M 2.63M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a 46.17K 37.12K -474.34K -111.83K n/a n/a n/a -314 n/a n/a n/a
Shares Outstanding (Basic)
90.01M 89.54M 69.36M 8.88M 7.54M 6.34M 6.19M 5.34M 5.23M 4.59M 4.2M 4.22M 4.2M 4.2M 4.21M 4.19M 2.04M 1.68M
Shares Outstanding (Diluted)
90.01M 89.54M 69.36M 8.88M 7.54M 6.34M 6.19M 5.34M 5.23M 4.59M 4.2M 4.22M 4.22M 4.2M 4.21M 4.19M 2.04M 1.68M
EPS (Basic)
-0.11 -0.15 -0.17 -0.65 -0.66 -0.73 -0.68 -0.86 -1.11 -0.87 -0.99 -1.06 -1.1 -1.1 -1.2 -1.07 -1.29 -1.57
EPS (Diluted)
-0.11 -0.15 -0.17 -0.65 -0.66 -0.73 -0.68 -0.86 -1.11 -0.87 -0.99 -1.06 -1.1 -1.1 -1.2 -1.07 -1.29 -1.57
EBITDA
-11.17M -15.75M -12.92M -5.82M -5.04M -4.78M -4.4M -4.76M -6.04M -4.71M -4.33M -4.51M -4.64M -4.64M -5.04M -4.47M -2.63M -2.63M
EBIT
-11.19M -15.76M -12.93M -5.83M -5.05M -4.78M -4.4M -4.77M -6.2M -4.71M -4.33M -4.51M -4.64M -4.64M -5.04M -4.47M -2.63M -2.63M
Depreciation & Amortization
24.16K 12.65K 6.57K 6.57K 6.57K 6.57K 6.57K 6.57K 159.2K 5.04K 5.04K 1.68K 4.64M 4.64M 5.04M 4.47M 2.63M 2.63M